We think this new name will serve us well as we move forward in developing products to provide long-term improvement in a wide range of respiratory diseases.
Rockville, Maryland (PRWEB) December 12, 2014
Clarassance, a privately held clinical-stage biotechnology company based in Maryland, today announced its new name: Therabron Therapeutics, Inc. The new name is derived from the words therapy and bronchioles (a type of structure in the lungs similar to branches on a tree), thus incorporating the company’s mission to develop novel protein therapeutics for the treatment of respiratory diseases.
“Our board of directors decided to change the name to mark the company's escalation into the clinical phase in which multiple clinical trials will be performed,” said Dr. Aprile Pilon, founder and CEO of Therabron Therapeutics. “We think this new name will serve us well as we move forward in developing products to provide long-term improvement in a wide range of respiratory diseases.”
Therabron’s lead product candidate, recombinant human CC10 protein (rhCC10), is a synthetic version of the native CC10 protein, a potent anti-inflammatory factor that is deficient in many respiratory diseases. RhCC10 has completed two Phase 1 clinical trials in which it was shown to be safe in infants and adults. It showed potent anti-inflammatory activity and significant long-term benefit in premature infants, who are known to lack sufficient native CC10 in their lungs. Therabron is currently conducting a Phase 2 randomized trial of CG100 (rhCC10) in pre-term infants, who are at great risk for developing Bronchopulmonary Dysplasia (BPD), a chronic lung disease ranging in severity from mild asthma to life-threatening pulmonary fibrosis. The trial is over 30 percent enrolled and is projected to take another 12 months to complete enrollment of a total of 88 very premature infants. Therabron plans to initiate a second trial for its CG201 drug candidate in 2015.
About Therabron Therapeutics, Inc.
Therabron Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2007 and located in Rockville, MD, to develop protein drugs to treat respiratory diseases. The company’s products aim to restore the natural immune balance in the lungs of respiratory patients through the administration of synthetic human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, have the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced in the past several decades. Therabron’s products have the potential to be first-to-market, first-in-class, disease-modifying, break-through biologics. For additional information, please visit http://www.therabron.com.